Shionogi & Co., Ltd. (SGIOF)

49.60 0.00 (0.00%) At close: 09:38AM EDT

Shionogi & Co., Ltd.

1-8, Doshomachi 3-chome
Chuo-ku
Osaka 541-0045
Japan
81 6 6202 2161
https://www.shionogi.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 5,680

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Isao Teshirogi Ph.D.	CEO, President & Representative Director	1.9M	N/A	1959
Susumu Mitsumori	Vice President of Finance & Accounting Department	N/A	N/A	N/A
Mr. Kazuhiro Hatanaka	Senior Executive Officer & Senior VP of Administration Division	N/A	N/A	N/A
Mr. Takeshi Shiota Ph.D.	Corporate Officer and Senior VP of Corporate Quality Assurance, Ethics & Compliance Management Div.	N/A	N/A	N/A
Mr. Yoshimasa Kyokawa	Vice President of Corporate Communications & Secretary Office	N/A	N/A	N/A
Yoshihiro Furuya	Vice President of General Marketing and Compliance Officer of Corporate GXP Compliance Office	N/A	N/A	N/A
Mr. Kohji Hanasaki Ph.D.	Senior Executive Officer and Senior VP of Supply Supervisory Unit & Global Business Division	N/A	N/A	N/A
Dr. John A. Keller Ph.D.	Senior Executive Officer and Senior VP of R&D Supervisory Unit	N/A	N/A	1965
Akira Kato Ph.D.	Corporate Officer & President of Shionogi Pharma Co., Ltd	N/A	N/A	N/A
Dr. Ryuichi Kiyama Ph.D.	Senior Executive Officer & Senior VP of Corporate Strategy Division	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer's disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

Corporate governance

Shionogi & Co., Ltd.’s ISS governance QualityScore as of 1 May 2024 is 1. The pillar scores are Audit: 1; Board: 1; Shareholder rights: 3; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.